|
2024
|
Invention
|
Adam9-binding molecules, and methods of use thereof.
The present invention is directed to molecu... |
|
|
Invention
|
B7-h3 antibody-drug conjugates. The present disclosure is directed to a B7-H3-ADC that comprises ... |
|
|
Invention
|
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof.
The p... |
|
|
Invention
|
Cd3-binding molecules capable of binding to human and non-human cd3.
The present invention relat... |
|
|
Invention
|
Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses there... |
|
2023
|
Invention
|
Lag-3-binding molecules and methods of use thereof.
The present invention is directed to the ant... |
|
|
Invention
|
Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4.
The present ... |
|
|
Invention
|
Multl-chain polypeptide-containing tri-specific binding molecules that specifically bind to multi... |
|
|
Invention
|
Methods for the treatment of disease using immunoglobulins having fc regions altered affinities f... |
|
|
Invention
|
Variant cd3-binding domains and their use in combination therapies for the treatment of disease. ... |
|
|
Invention
|
Tri-specific binding molecules that specifically bind to multiple cancer antigens.
The present i... |
|
|
Invention
|
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof.
CD1... |
|
|
Invention
|
Compound targeting il-23a and tnf-alpha and uses thereof.
The disclosure relates to compounds sp... |
|
|
Invention
|
Pd-1-binding molecules and methods of use thereof.
The present invention is directed to selected... |
|
|
Invention
|
Methods for the use of a b7-h3 antibody-drug conjugate in combination with a pd-1 x ctla-4 bispec... |
|
|
Invention
|
Covalent diabodies and uses thereof.
The present invention is directed to diabody molecules and ... |
|
|
Invention
|
B7-h3 directed antibody drug conjugates.
The present invention is directed to novel B7-H3-bindin... |
|
2022
|
Invention
|
Bispecific molecules that are immunoreactive with immune effector cells that express an activatin... |
|
|
Invention
|
Pharmaceutical compositions of a b7-h3 antibody and use of the same.
The present invention provi... |
|
|
Invention
|
Pharmaceutical compositions of a b7-h3 antibody and use of the same. The present invention provid... |
|
|
Invention
|
Pharmaceutical compositions of a pd-1 antibody and use of the same.
The present disclosure is pr... |
|
|
Invention
|
Pharmaceutical compositions of a pd-1 antibody and use of the same. The present disclosure is pro... |
|
|
Invention
|
Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof.... |
|
|
Invention
|
Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer. ... |
|
2021
|
Invention
|
Pharmaceutical compositions of a her2/neu antibody and use of the same. i.e.i.e., a cancer that e... |
|
|
Invention
|
Methods and compositions for treatment of lupus.
Disclosed herein, in one aspect, is a method of... |
|
|
Invention
|
Methods and compositions for treatment of lupus. Disclosed herein, in one aspect, is a method of ... |
|
|
Invention
|
Combination therapy for the treatment of cancer.
The present invention is directed to a combinat... |
|
|
Invention
|
Methods for the use of a pd-1 x ctla-4 bispecific molecule.
The present invention is directed in... |
|
|
Invention
|
Methods for the use of a pd-1 x ctla-4 bispecific molecule. The present invention is directed in ... |
|
|
Invention
|
Fcgammariib-specific antibodies and methods of use thereof.
The present invention relates to ant... |
|
|
Invention
|
Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use there... |
|
|
Invention
|
Use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies.
The prese... |
|
|
Invention
|
Use of bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies. The presen... |
|
|
Invention
|
Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination.
The present inve... |
|
|
P/S
|
Pharmaceutical preparations and substances for use in the treatment of autoimmune disorders, infl... |
|
|
P/S
|
Pharmaceutical preparations and substances for use in the
treatment of autoimmune disorders, inf... |
|
|
Invention
|
Cd137 binding molecules and uses thereof.
The present invention is directed to binding molecules... |
|
2020
|
Invention
|
Therapy for the treatment of cancer.
The present invention is directed to regimens for administe... |
|
|
Invention
|
Pharmaceutical formulations of bi-specific diabodies and use of the same.
The present invention ... |
|
|
Invention
|
Dosing regimens of bispecific cd123 x cd3 diabodies in the treatment of hematologic malignancies.... |
|
|
P/S
|
New product commercialization services, namely, commercialization for third parties of pharmaceut... |
|
2018
|
P/S
|
Pharmaceutical preparations and substances for use in the treatment of cancer |
|
2015
|
P/S
|
Product commercialization for third parties of pharmaceuticals and substances for the treatment o... |
|
2013
|
P/S
|
Production and product commercialization for third parties of pharmaceuticals and substances, nam... |
|
2010
|
P/S
|
Production and product commercialization for third parties of pharmaceuticals and substances for ... |
